Browsing by Author "Hudmon, Andy"

Now showing 1 - 1 of 1
  • Thumbnail Image
    ItemOpen Access
    Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2)
    (The American Society for Biochemistry and Molecular Biology, Inc., 2011-08-09) Brittain, Joel M.; Chen, Liang; Wilson, Sarah M.; Brustovetsky, Tatiana; Gao, Xiang; Ashpole, Nicole M.; Molosh, Andrei I.; You, Haitao; Hudmon, Andy; Shekhar, Anantha S.; White, Fletcher A.; Zamponi, Gerald W.; Brustovetsky, Nickolay N.; Chen, Jinhui; Khanna, Rajesh
    Neurological disabilities following traumatic brain injury (TBI) may be due to excitotoxic neuronal loss. The excitotoxic loss of neurons following TBI occurs largely due to hyperactivation of N-methyl-d-aspartate receptors (NMDARs), leading to toxic levels of intracellular Ca(2+). The axon guidance and outgrowth protein collapsin response mediator protein 2 (CRMP2) has been linked to NMDAR trafficking and may be involved in neuronal survival following excitotoxicity. Lentivirus-mediated CRMP2 knockdown or treatment with a CRMP2 peptide fused to HIV TAT protein (TAT-CBD3) blocked neuronal death following glutamate exposure probably via blunting toxicity from delayed calcium deregulation. Application of TAT-CBD3 attenuated postsynaptic NMDAR-mediated currents in cortical slices. In exploring modulation of NMDARs by TAT-CBD3, we found that TAT-CBD3 induced NR2B internalization in dendritic spines without altering somal NR2B surface expression. Furthermore, TAT-CBD3 reduced NMDA-mediated Ca(2+) influx and currents in cultured neurons. Systemic administration of TAT-CBD3 following a controlled cortical impact model of TBI decreased hippocampal neuronal death. These findings support TAT-CBD3 as a novel neuroprotective agent that may increase neuronal survival following injury by reducing surface expression of dendritic NR2B receptors.